Unlocking the Cures for America's Most Deadly Diseases, Hearing Before the Subcommittee on Space, Science, and Competitiveness of the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Fourteenth Congress, First Session, July 14, 2015   [open pdf - 2MB]

This is the July 14, 2015 hearing on "Unlocking the Cures for America's Most Deadly Diseases," held before the United States Senate Committee on Commerce, Science, and Transportation. From the opening statement of Ted Cruz, "We are here today to discuss an issue that is important to every one of us. We are here today to discuss cures-cures to life threatening diseases, cures to diseases that devastate the lives of millions. We are here today to discuss what we are doing well and what we could be doing better to open new frontiers. The United States has led the world in path-breaking medical research and yet there is far more we could be doing. In the year 2015, it is estimated almost 600,000 Americans face cancer. Another 700,000 with Alzheimer's Disease are expected to die this year. Nearly 500,000 people in the United States suffer from the effects of Parkinson's Disease. 795,000 suffer strokes each year. 25.8 million people are afflicted with diabetes, and 95 percent of other rare diseases currently have no recognized treatments or cures, leaving most of the 30 million patients afflicted by them with few or no options. The path to achieving medical breakthroughs in cures is long and capital intensive. Often it seems when it comes to medical research we are pennywise and pound foolish, that we pay billions or trillions on the back end, dealing with the consequences of horrific diseases, rather than investing and creating the incentives on the front end to cure these diseases once and for all. The average cost to get a single drug approved by the FDA is between $1 billion and $2 billion. In addition, the regulatory burdens and bureaucratic unpredictability slow the ability of innovators to create new cures. Regulatory burdens and uncertainty are also having an effect on private investment." Statements, letters, and materials submitted for the record include those of the following: Tom Coburn, Christopher Frangione, Peter W. Huber, and Keith R. Yamamoto.

Report Number:
S. Hrg. 114-102; Senate Hearing 114-102
Public Domain
Retrieved From:
Government Printing Office: http://www.gpo.gov/
Media Type:
Help with citations